Tocolytic therapy with hexoprenaline in pregnant women at risk for premature birth. The impact of ADRB2 gene polymorphism on tocolysis
DOI: https://doi.org/10.29296/25877305-2021-09-08
Issue:
9
Year:
2021
Premature birth (PB) is the main cause of mortality and morbidity in newborns without congenital
malformations or chromosomal aberrations. Objective: to evaluate the significance of the ADRB2 gene
polymorphism in predicting the efficiency and safety of tocolytic pharmacotherapy with β2-adrenostimulants
in pregnant women with PB. Subjects and methods. The investigation involved 120 pregnant women, including 60
women at risk for PB who received tocolytic therapy with hexoprenaline as indicated; and 60 ones at no risk
for PB. The Gly16Arg and Gln27Glu polymorphisms in the ADRB2 gene were determined in all the study
participants. The findings were compared with the indicators of the efficiency and safety of hexoprenaline
therapy. Results. The 16Arg allele of the ADRB2 gene was 1.54 times more common in parturients with a normal
pregnancy than in patients at risk for PB (the result was insignificant at the accepted significance level,
but close to it: χ2=3.8218; p=0.05059). Hexoprenaline therapy prolonged pregnancy to a period of >37
weeks in 65% of the patients with PB. The efficacy of hexoprenaline was lower in the carriers of the
genotypes indicating the high or low expression of β2-adrenoreceptors.
Keywords:
obstetrics and gynecology
premature birth
hexoprenaline
genotyping
single nucleotide polymorphisms
ADRB2
References:
- Serov V.N., Tjutjunnik V.L. Taktika lechenija ugrozhajuschih prezhdevremennyh rodov. RMZh. 2008; 16 (19): 1252–5 [Serov V.N., Tyutyunnik V.L. Tactics for the treatment of threatened premature birth. RMJ. 2008; 16 (19): 1252–5 (in Russ.)].
- Surina M.N., Chvanova E.A. Techenie beremennosti i ee ishody u patsientok s defitsitom massy tela. Fundamental'naja i klinicheskaja meditsina. 2018; 3 (3): 65–70 [Surina M.N., Chvanova E.A. Pregnancy course and outcomes in women with low body mass index. Fundamental and Clinical Medicine. 2018; 3 (3): 65–70 (in Russ.)]. DOI: 10.23946/2500-0764-2018-3-3-65-70
- Haas D.M., Quinney S.K., McCormick .CL. et al. A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. J Matern Fetal Neonatal Med. 2012; 25 (4): 419–23. DOI: 10.3109/14767058.2011.583700
- Miller R.S., Smiley R.M., Daniel D. et al. Beta-2 adrenoceptor genotype and progress in term and late preterm active labor. Am J Obstet Gynecol. 2011; 205 (2): 137.e1–137.e7. DOI: 10.1016/j.ajog.2011.03.045